Command Polymers (543843)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE is positive at 4.73%, indicating the existing capital is still earning a small positive return.
• The latest quarter shows revenue of ₹2 Cr, so the business is continuing to operate despite the severe sales decline.
• At ₹26.70, the stock is only about 16% above its 52-week low of ₹23.00, offering a defined price reference for disciplined monitoring.

Concerns

• Sales growth of -76.83% and profit growth of -33,100% signal severe fundamental deterioration.
• Latest quarter net loss of ₹3 Cr against sales of ₹2 Cr; annualised, that loss is huge relative to the ₹26 Cr market cap.
• Piotroski F-score of 3/9 suggests poor financial health; there is also no dividend while the company burns cash.
• Critical data is missing or unreliable: no book value, debt/equity, promoter holding, or ROE, and the reported P/E of 40.18 is misleading given recent losses.

AI Analysis

When I look at Command Polymers, I see a tiny industrial plastics company with a market cap of just ₹26 crore. Since I like to know what I'm buying, the first thing that bothers me is the inadequate disclosure: no book value, no debt-to-equity, no promoter holding. Graham taught me that without facts, investment analysis is guesswork. The numbers we do have paint a troubled picture. Sales have collapsed by 76.83%, and profit growth of -33,100% is a staggering negative number. The latest quarter tells the same story: ₹2 crore in sales and a ₹3 crore net loss. An annualized loss of roughly ₹12 crore against a ₹26 crore market cap is not a margin of safety; it is a cash incinerator. The stated P/E of 40.18 is therefore misleading, because recent earnings are negative. ROCE of 4.73% is positive, but far below what I would need to compensate for such business risk. The Piotroski F-score of only 3/9 confirms weak fundamental health. There is no dividend to pay me while I wait. At ₹26.70, near the low of a ₹23.00-₹32.68 range, the share looks cheap only in price, not in value. In the absence of a clear moat, pricing power, or profitable growth, I cannot classify this as a quality compounder. It might be a distressed turnaround at best, but Ben Graham always insisted on a margin of safety. With losses mounting and data missing, the prudent action is to watch from the sidelines. If the company can stabilize sales, return to positive net profit, and provide full financials, then I might revisit. Until then, hope is not an investment strategy.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer